Pepmoron dumping MYG b4 bad news!!!Just Yesterday, Pepmoron wrote this, urging you to buy Methylgene on false rumor of roche buying it!!!
Beware of the scam artist!!!!!
https://www.stockhouse.com/Bullboards/MessageDetail.aspx?s=TLN&t=LIST&m=27172717&l=0&pd=0&r=0
Look at today's TERRIBLE NEWS1!!
methylgene fires CHIEF Scientist one day before ASCO!!!!!!!!!
MethylGeneInc. (TSX: MYG) is a publicly-traded, clinical stage, biopharmaceuticalcompany focused on the discovery, development and commercialization ofnovel therapeutics for cancer. The Company’s product candidatesinclude: MGCD265, an oral, multi-targeted kinase inhibitor targetingthe c-Met, VEGF, Ron and Tie-2 receptor tyrosine kinases that is inPhase I clinical trials for solid tumor cancers; MGCD290, a fungal Hos2(HDAC) inhibitor being developed for use in combination withfluconazole for serious fungal infections that is also in Phase Iclinical studies; and MGCD0103, an oral, isoform-selective HDACinhibitor which has been in multiple clinical trials for solid tumorsand hematological malignancies and is licensed to Taiho PharmaceuticalCo. Ltd. A fourth compound discovered using MethylGene’s HDAC platform,EVP-0334 - a potential cognition enhancing agent, is in a Phase I studysponsored by EnVivo Pharmaceuticals Inc. MethylGene also has a fundedcollaboration with Otsuka Pharmaceutical Co. Ltd. for applications inocular diseases using the Company’s proprietary kinase inhibitorchemistry. Please visit our website at /www.methylgene.com/">www.methylgene.com.